Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 127
Filter
1.
Synapse ; 45(1): 1-9, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12112408

ABSTRACT

PET and [(11)C]CP-126,998, an N-benzylpiperidinebenzisoxazole, were used to image brain acetylcholinesterase (AChE) distribution in healthy controls before and after administration of 5 mg donepezil p.o., a reversible AChE inhibitor. Logan plots were used to compute distribution volumes (V(T)). The V(T) of [(11)C]CP-126,998 was highest in the basal ganglia and cerebellum and lowest in the cerebral cortex, thalamus, amygdala, and hippocampus. The regional V(T) values correlated well with AChE concentration measured in vitro. Donepezil, given 4 h before PET scanning, induced a substantial inhibition of [(11)C]CP-126,998 binding (43-62%) in all brain regions when compared to the baseline PET study. The results of this study indicate that PET imaging of [(11)C]CP-126,998 may be useful in quantifying the distribution of regional brain AChE. This new PET radiotracer may potentially be employed in the diagnosis and treatment of patients with disorders of cholinergic neurotransmission, such as Alzheimer's disease.


Subject(s)
Acetylcholinesterase/metabolism , Brain/diagnostic imaging , Brain/enzymology , Cholinesterase Inhibitors/pharmacokinetics , Isoxazoles/pharmacokinetics , Piperidines/pharmacokinetics , Tomography, Emission-Computed , Adult , Animals , Carbon Radioisotopes , Cholinesterase Inhibitors/pharmacology , Donepezil , Dose-Response Relationship, Radiation , Humans , Indans/pharmacology , Kinetics , Male , Mice , Piperidines/pharmacology , Tissue Distribution
2.
Nucl Med Biol ; 28(8): 911-21, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11711310

ABSTRACT

Three 3-pyridyl ether nicotinic ligands-(S)-5-Iodo-3-[(2-pyrrolidinyl)-methoxy]pyridine (5-iodo-A-85865), (S)-5-Iodo-3-[1-(methyl)-2-pyrrolidinyl-methoxy]pyridine (5-Iodo-A-84543), and (S)-5-iodo-3-[1-methyl-(2-azetidinyl)-methoxy]pyridine (5-iodo-N-Me-A-85380) were labeled with I-125/I-123, and their ability to label high-affinity brain nicotinic acetylcholine receptors (nAChRs) was evaluated. The most promising ligand, [123/125I] 5-iodo-A-85865, showed approximately 65% inhibition of radioactivity uptake in thalamus in mice pretreated with cytisine. Preliminary SPECT imaging studies with [123I] 5-iodo-A-85865 revealed a distribution profile consistent with nAChRs (thalamus > frontal cortex > cerebellum) and a more rapid pharmacokinetic profile relative to azetidinyl 3-pyridyl ether based ligands.


Subject(s)
Brain/diagnostic imaging , Ethers/chemical synthesis , Pyridines/chemical synthesis , Receptors, Nicotinic/metabolism , Animals , Ethers/metabolism , Ethers/pharmacokinetics , Male , Mice , Papio , Pyridines/metabolism , Pyridines/pharmacokinetics , Tissue Distribution , Tomography, Emission-Computed, Single-Photon
3.
J Nucl Med ; 42(8): 1274-80, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11483691

ABSTRACT

UNLABELLED: Endothelin (ET) is a potent mammalian vasoconstrictive peptide and a pressor agent. Its 3 isoforms, ET-1, ET-2, and ET-3, mediate several physiologic actions in several organ systems, binding to 2 major receptor subtypes: ET(A) and ET(B). This study was undertaken to evaluate [(11)C]L-753,037 [(+)-(5S,6R,7R)-2-butyl-7-[2-((2S)-2-carboxy-propyl)-4-methoxyphenyl]-5-(3,4-methylenedioxyphenyl)cyclopenteno [1,2-beta]pyridine-6-carboxylate), a new mixed ET receptor A and B antagonist, as a tracer for in vivo labeling of ET receptors in mice and a dog. METHODS: [(11)C]L-753,037 was synthesized, purified, and formulated from a normethyl precursor, L-843,974, and [(11)C]H(3)I. The tracer was studied for its in vivo kinetics, biodistribution, and ET receptor binding characteristics in mice. In the dog, PET imaging was performed to evaluate binding of [(11)C]L-753,037 to ET receptors in the heart. Specificity of binding was studied in the heart with the selective ET(A) antagonist L-753,164. RESULTS: Kinetic studies in mice showed highest tracer uptake at 5 min after injection in liver (25.0 percentage injected dose per gram [%ID/g]), kidneys (18.7 %ID/g), lungs (15.2 %ID/g), and heart (5.6 %ID/g). Initial high uptake in liver, lungs, and kidneys was followed by rapid washout during the next 10 min and a very slow clearance during the time of observation (2 h after injection). By contrast, the radioactivity in the heart remained constant over 2 h. Administration of both ET(A) (L-753,164) and mixed ET(A)/ET(B) (L-753,137) receptor antagonists resulted in dose-dependent inhibition of [(11)C]L-753,037 binding in mouse heart, lungs, and kidneys but not in the liver. Radioactivity in the brain was very low, indicating that the tracer does not cross the blood-brain barrier. In the dog, a dynamic PET study of the heart showed high tracer accumulation at 55-95 min after injection. Injection of L-753,164 at 30 min before [(11)C]L-753,037 administration led to a significant reduction in tracer binding. [(11)C]methyl triphenyl phosphonium was used as a tracer for reference images of the dog heart muscle. CONCLUSION: The results suggest that [(11)C]L-753,037 binds to ET receptors in vivo and is, therefore, a promising candidate for investigation of these receptors and their occupancy by ET receptor antagonists using PET.


Subject(s)
Endothelin Receptor Antagonists , Pyridines , Radiopharmaceuticals , Animals , Dogs , Isotope Labeling , Mice , Pyridines/pharmacokinetics , Receptor, Endothelin A , Receptor, Endothelin B , Receptors, Endothelin/metabolism , Species Specificity , Tissue Distribution , Tomography, Emission-Computed
4.
J Nucl Med ; 41(8): 1417-25, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10945536

ABSTRACT

UNLABELLED: The objectives of this study were to synthesize neuronal nitric oxide synthase (NOS-I)-selective imaging agents based on the 2 potent, selective inhibitors AR-R 17443 [N-(4-((2-((phenylmethyl) (methyl)-amino)ethyl)phenyl)-2-thiophenecarboximidamide)] and AR-R 18512 [(N(2-methyl-1,2,3,4-tetrahydroisoquinoline-7-yl)-2-thiophenecarboxim idamide)] in positron-emitting form and to evaluate regional brain uptake in rodents and primates. METHODS: [11C]AR-R 17443 and [11C]AR-R 18512 were produced by N-alkylation of the corresponding desmethyl precursors using [11C]iodomethane. Regional brain uptake of [11C]AR-R 17443 and [11C]AR-R 18512 was assayed in rats and NOS-I knockout mice, and PET was performed in baboons. Tracer kinetic modeling used a 2-compartment plasma and brain tissue model. RESULTS: Yields of [11C]AR-R 17443 and [11C]AR-R 18512 ranged from 8% to 16% at the end of synthesis, with specific activities of 50-178 GBq/micromol (1,350-4,800 Ci/mmol) at the end of synthesis. In rat cerebellum and cortex at 30 min after injection, [11C]AR-R 17443 showed 1.01 +/- 0.01 and 1.63 +/- 0.12 percentage injected dose per gram (%ID/g) uptake, respectively, whereas [11C]AR-R 18512 showed 0.88 +/- 0.01 and 1.30 +/- 0.07 %ID/g uptake, respectively. Attempts to block tracer uptake by pretreatment with the NOS-I-selective inhibitor 7-nitroindazole or the corresponding unlabeled inhibitor (or desmethyl precursor to AR-R 17443 of similar potency) were unsuccessful. A small but significant (20%) decrease in cerebellar uptake of [11C]AR-R 18512 was present in NOS-I knockout mice compared with control mice. PET of [11C]AR-R 18512 in baboons with concurrent regional cerebral blood flow (rCBF) determination before and after administration of blocker showed dose-related decreases in cerebellar uptake that were greater than or equal to decreases in rCBF. Plasma metabolites accounted for 27% of total activity at 30 min after injection. Kinetic modeling of binding potentials revealed a distribution volume of 334 in cerebral blood that dropped 51% after blocker administration. CONCLUSION: Rodent studies for [11C]AR-R 17443 and [11C]AR-R 18512 showed little evidence of specific NOS-I binding. In baboons, we detected a higher uptake of [11C]AR-R 18512 in the cerebellum than in the cortex (approximately 5%, accounting for decreased rCBF because of blockade), indicating minimal specific binding. Analogs of higher affinity are likely required if this class of agents is to prove viable for PET.


Subject(s)
Brain/diagnostic imaging , Brain/enzymology , Enzyme Inhibitors/pharmacokinetics , Isoquinolines/pharmacokinetics , Nitric Oxide Synthase/analysis , Tetrahydroisoquinolines , Thiophenes/pharmacokinetics , Tomography, Emission-Computed , Animals , Blood-Brain Barrier , Carbon Radioisotopes/pharmacokinetics , Enzyme Inhibitors/chemical synthesis , Isoquinolines/chemical synthesis , Male , Mice , Mice, Knockout , Models, Biological , Nitric Oxide Synthase/deficiency , Nitric Oxide Synthase Type I , Organ Specificity , Papio , Rats , Rats, Sprague-Dawley , Thiophenes/chemical synthesis , Tissue Distribution
5.
Nucl Med Biol ; 27(1): 51-6, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10755645

ABSTRACT

6-[18F]Fluoro-3-(2(S)-azetidinylmethoxy)pyridine (6-[18F]fluoro-A-85380 or 6-[18F]FA), a new tracer for positron emission tomography, was synthesized by no-carrier-added [18F] fluorination of 6-iodo-3-((1-tert-butoxycarbonyl-2(S)-azetidinyl)methoxy)pyridine followed by acidic deprotection. 6-[18F]FA followed the regional densities of brain nicotinic acetylcholine receptors (nAChRs) reported in the literature. Evidence of binding to nAChRs and high specificity of the binding in vivo was demonstrated by inhibition with nAChR selective ligands as well as with unlabeled 6-FA. A preliminary toxicology study of the 6-FA showed a relatively low biological effect.


Subject(s)
Azetidines/chemical synthesis , Azetidines/pharmacokinetics , Brain/metabolism , Receptors, Nicotinic/metabolism , Animals , Azetidines/metabolism , Brain/diagnostic imaging , Fluorine Radioisotopes , Injections, Subcutaneous , Male , Mice , Mice, Inbred ICR , Radiochemistry , Tissue Distribution , Tomography, Emission-Computed
6.
Toxicol Lett ; 112-113: 143-6, 2000 Mar 15.
Article in English | MEDLINE | ID: mdl-10720723

ABSTRACT

The recreational drug, (+/-)3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), is a potent serotonin (5-HT) neurotoxin in animals. Whether humans who use MDMA incur 5-HT neural injury is unknown. The present studies utilized positron emission tomography (PET) in conjunction with the 5-HT transporter ligand, [11C]McN-5652 to assess the status of brain 5-HT neurons in human MDMA users. Like nonhuman primates treated with neurotoxic doses of MDMA, humans with a history of MDMA use showed lasting decrements in global brain [11C]McN-5652 binding, with decreases in [11C]McN-5652 binding positively correlated to the extent of previous MDMA use. These results suggest that human MDMA use results in brain 5-HT neurotoxicity.


Subject(s)
Brain/drug effects , N-Methyl-3,4-methylenedioxyamphetamine/pharmacology , Serotonin Agents/pharmacology , Animals , Brain/metabolism , Chromatography, High Pressure Liquid , Female , Humans , Isoquinolines/metabolism , Male , N-Methyl-3,4-methylenedioxyamphetamine/blood , N-Methyl-3,4-methylenedioxyamphetamine/toxicity , Neurons/drug effects , Papio , Serotonin Agents/blood , Serotonin Agents/toxicity , Serotonin Antagonists/metabolism , Tomography, Emission-Computed
7.
Nucl Med Biol ; 27(8): 757-62, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11150708

ABSTRACT

ABSTRACT. [(18)F] SR144385 and [(18)F] SR147963 were synthesized in a multistep reaction in which fluorine-18 was introduced by nucleophilic halogen displacement on a bromo precursor. The fluorine-18-labeled intermediate was deprotected and coupled with the appropriate alkyl amine to give the final products. Both radioligands had appropriate regional brain distribution for cannabinoid receptors with a target to nontarget ratio of 1.7 for [(18)F] SR147963 and 2.5 for [(18)F] SR144385 at 60 and 90 min postinjection, respectively. The uptake of both tracers was blocked with a 1 mg/kg dose of SR141716A.


Subject(s)
Brain/metabolism , Cannabinoids/metabolism , Morpholines/pharmacokinetics , Piperidines/pharmacokinetics , Pyrazoles/pharmacokinetics , Radiopharmaceuticals/pharmacokinetics , Receptors, Drug/metabolism , Administration, Inhalation , Animals , Brain/diagnostic imaging , Chromatography, High Pressure Liquid , Fluorine Radioisotopes , Isotope Labeling , Ligands , Male , Mice , Morpholines/administration & dosage , Morpholines/metabolism , Piperidines/administration & dosage , Piperidines/metabolism , Pyrazoles/administration & dosage , Pyrazoles/metabolism , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/metabolism , Receptors, Cannabinoid , Tissue Distribution , Tomography, Emission-Computed
8.
J Cereb Blood Flow Metab ; 19(9): 967-81, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10478648

ABSTRACT

The impulse response function of a radioligand is the most fundamental way to describe its pharmacokinetics and to assess its tissue uptake and retention pattern. This study investigates the impulse response function of [11C](+)McN5652, a radioligand used for positron emission tomography (PET) imaging of the serotonin transporter (SERT) in the brain. Dynamic PET studies were performed in eight healthy volunteers injected with [11C](+)McN5652 and subsequently with its pharmacologically inactive enantiomer [11C](-)McN5652. The impulse response function was calculated by deconvolution analysis of regional time-activity curves, and its peak value (f(max)), its retention value at 75 minutes (fT), and its normalized retention (f(rel) = fT/f(max)) were obtained. Alternatively, compartmental models were applied to calculate the apparent total distribution volume (DV(T)) and its specific binding component (DV(S)). Both the noncompartmental (fT,f(rel)) and the compartmental parameters (DV) were investigated with and without correction for nonspecific binding by simple subtraction of the corresponding value obtained with [11C](-)McN5652. The impulse response function obtained by deconvolution analysis demonstrated high tracer extraction followed by a slow decline in the form of a monoexponential function. Statistical analysis revealed that the best compartmental model in terms of analysis of variance F and condition number of the parameter variance-covariance matrix was the one that was based on a single tissue compartment with parameters k1 and k2 and that also included the parameter of regional cerebral blood volume (BV). The parameter f(rel) demonstrated low between-subject variance (coefficient of variation [CV] = 19%), a midbrain to cerebellum ratio of 1.85, and high correlation with the known density of SERT (r = 0.787 where r is the coefficient of linear correlation between the parameter and the known density of SERT). After correction for nonspecific binding, f(rel) demonstrated further improvement in correlation (r = 0.814) and midbrain to cerebellum ratio (3.09). The variance of the distribution volumes was acceptable when the logarithmic transform lnDV was used instead of DV (17% for the three-parameter model), but correlation of this compartmental parameter was slightly less (r = 0.652 for the three-parameter model) than the correlation of the noncompartmental f(rel) with the known density of SERT, and the midbrain to cerebellum ratio was only 1.5 (uncorrected) and 1.8 (corrected). At the expense of increasing variance, the correlation was increased after correction for nonspecific binding using the inactive enantiomer (r = 0.694; CV = 22%). These results indicate that the kinetics of [11C](+)McN5652 can best be described by a one-tissue compartment model with three parameters (k1, k2, and BV), and that both the noncompartmental parameter f(rel) and the compartmental distribution volumes have the potential for quantitative estimation of the density of SERT. Further validation of the radioligand in experimental and clinical situations is warranted.


Subject(s)
Brain/metabolism , Carrier Proteins/antagonists & inhibitors , Carrier Proteins/metabolism , Isoquinolines/administration & dosage , Membrane Glycoproteins/antagonists & inhibitors , Membrane Glycoproteins/metabolism , Membrane Transport Proteins , Serotonin Antagonists/administration & dosage , Adult , Brain/diagnostic imaging , Female , Humans , Kinetics , Male , Models, Biological , Nerve Tissue Proteins/metabolism , Radiography , Radioligand Assay , Serotonin Plasma Membrane Transport Proteins , Tomography, Emission-Computed
9.
J Nucl Med ; 40(7): 1180-5, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10405140

ABSTRACT

UNLABELLED: In vitro studies have demonstrated the membrane potential-dependent enhanced uptake of phosphonium salts, including [3H]triphenylmethylphosphonium (TPMP), into mitochondria of carcinoma and glioma-derived tumor cells, suggesting the potential use of phosphonium salts as tracers for tumor imaging. This study characterizes the in vivo uptake of [11C]TPMP in canine brain glioma using PET. METHODS: Dynamic paired PET studies of [11C]TPMP followed by [68Ga]ethylenediaminetetraacetic acid (EDTA) were performed 4 d before and 9 d after tumor cell inoculation. Graphical analysis was used to evaluate [11C]TPMP retention in tumor tissue. Distribution of tracer uptake was compared with tumor histological sections. RESULTS: [11C]TPMP exhibited enhanced uptake and prolonged retention in tumor cells. Patlak plot was linear over the 20- to 95-min postinjection period (r = 0.97 +/- 0.1). [68Ga]EDTA exhibited a gradual washout from the tumor tissue. The tumor-to-normal brain uptake ratio at 55 to 95 min postinjection was 47.5 for [11C]TPMP and 8.1 for [68Ga]EDTA. Qualitative comparison with histological sections indicated that [11C]TPMP enhanced uptake was restricted to the tumor area. CONCLUSION: The enhanced uptake and prolonged retention in tumor suggest [11C]TPMP as a promising means for imaging of gliomas in dogs. The need for studies in humans is indicated.


Subject(s)
Brain Neoplasms/diagnostic imaging , Gliosarcoma/diagnostic imaging , Onium Compounds , Tomography, Emission-Computed , Trityl Compounds , Animals , Carbon Radioisotopes , Dogs , Edetic Acid , Gallium Radioisotopes , Mice , Mice, Nude , Neoplasm Transplantation , Radiopharmaceuticals
10.
Ann Nucl Med ; 13(2): 101-7, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10355954

ABSTRACT

The present study was carried out to investigate the time course of [11C]pyrilamine metabolism and the degree of entry of metabolites into the brain. PET studies were performed in seven healthy volunteers and arterial plasma concentrations of [11C]pyrilamine and its labeled metabolites were determined. After intravenous injection, [11C]pyrilamine metabolized gradually in the human body, with less than 10% of plasma activity being original radioligand at 60 min. Tracer metabolism markedly affected the input function and the calculated impulse response function of the brain. Rat experiments demonstrated that although metabolites of [11C]pyrilamine might enter the brain, they were not retained for prolonged periods of time. At 30-90 min after injection of [11C]pyrilamine, less than 1% of the radioactivity in the brain was originating from metabolites of [11C]pyrilamine. Based on the rat data, the contribution of 11C-labeled metabolites to total [11C]pyrilamine radioactivity in the human brain was estimated and found to be negligible. These results suggest that the metabolites of [11C]pyrilamine do not accumulate within the cerebral extravascular space and that there is minimal metabolism of [11C]pyrilamine by brain tissue itself. Therefore, [11C]pyrilamine metabolites can be neglected in kinetic analysis, using either a compartmental or a noncompartmental model, of the [11C]pyrilamine binding to histamine H1 receptors.


Subject(s)
Brain/diagnostic imaging , Brain/metabolism , Pyrilamine/metabolism , Receptors, Histamine H1/metabolism , Tomography, Emission-Computed , Adult , Animals , Binding Sites , Carbon Radioisotopes/metabolism , Humans , Male , Pyrilamine/blood , Radioactive Tracers , Radiopharmaceuticals/blood , Radiopharmaceuticals/metabolism , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Sprague-Dawley
11.
Nucl Med Biol ; 26(2): 201-7, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10100220

ABSTRACT

A radiosynthetic method to prepare the nicotinic acetylcholine receptor radioligand (S)-5-[123I]iodo-3-(2-azetidinylmethoxy)pyridine, 5-IA, has been developed. The two-step sequence produced [123I]-5-IA in high radiochemical yield (52%), high radiochemical purity (98%), and high specific radioactivities (> 8,500 mCi/mumol). Preliminary single photon emission computed tomography studies with [123I]-5-IA in baboon demonstrated the appropriate regional localization for a high-affinity nicotinic radioprobe (thalamus > frontal cortex > cerebellum). Pretreatment with cytisine blocked [123I]-5-IA uptake in all brain regions (78-59% reduction), demonstrating the specificity of the radiotracer.


Subject(s)
Azetidines/chemical synthesis , Receptors, Nicotinic/analysis , Tomography, Emission-Computed, Single-Photon/methods , Animals , Brain/diagnostic imaging , Iodine Radioisotopes , Male , Molecular Structure , Papio , Radiochemistry , Radioligand Assay , Rats , Rats, Sprague-Dawley
12.
Nucl Med Biol ; 26(7): 737-41, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10628552

ABSTRACT

GR89696, racemic methyl 4-[(3,4-dichlorophenyl)acetyl]-3-[(1-pyrrolidinyl) methyl]-1-piperazinecarboxylate, a kappa opioid receptor ligand, was labeled with [11C]methyl chloroformate. The radiochemical yield was 20% with an observed specific radioactivity of 75.5 GBq/micromol at end of synthesis (2,040 mCi/micromol). Five minutes after intravenous administration, 5.4% of the injected dose accumulated in mouse whole brain. Brain region to cerebellar ratios increased over time with ratios at 90 min of 7.8, 5.6, and 4.5 for the hypothalamus, olfactory tubercle, and striatum, respectively. The uptake of [11C]GR89696 correlated with known kappa opioid receptor densities and was inhibited by kappa opioid selective drugs.


Subject(s)
Benzeneacetamides , Piperazines/chemical synthesis , Piperazines/metabolism , Pyrrolidines/chemical synthesis , Pyrrolidines/metabolism , Radiopharmaceuticals/chemical synthesis , Radiopharmaceuticals/metabolism , Receptors, Opioid, kappa/metabolism , Animals , Binding, Competitive , Brain/metabolism , Carbon Radioisotopes/chemistry , Dopamine Antagonists/metabolism , Dopamine Antagonists/pharmacology , Isotope Labeling , Ketanserin/metabolism , Ketanserin/pharmacology , Mice , Piperazines/isolation & purification , Piperazines/pharmacokinetics , Pyrrolidines/isolation & purification , Pyrrolidines/pharmacokinetics , Pyrrolidines/pharmacology , Radiopharmaceuticals/isolation & purification , Radiopharmaceuticals/pharmacokinetics , Receptors, Opioid, kappa/agonists , Receptors, Opioid, kappa/antagonists & inhibitors , Serotonin Antagonists/metabolism , Serotonin Antagonists/pharmacology , Spiperone/metabolism , Spiperone/pharmacology , Tissue Distribution
13.
IDrugs ; 2(2): 129-45, 1999 Feb.
Article in English | MEDLINE | ID: mdl-16160948

ABSTRACT

Loss of 5-HT transporter (SERT) sites has been implicated in various neurodegenerative diseases and users of some amphetamine derivatives such as MDMA. Therefore, the development of suitable radioligands for neuroimaging of the SERT in the human brain is important. A large number of drugs have been labeled with 11C, 18F or (123)I over the last ten years in order to achieve such radioligands. Despite these attempts most of the compounds were found unsuitable because of low target-to-nontarget ratios. Some cocaine-derived radioligands allow SERT imaging of the human brain using positron emission tomography (PET) although they have a limited selectivity. Among the various specific 5-HT uptake inhibitors only [(123)I]iodo-nitroquipazine for single photon emission computed tomography (SPECT) and [11C](+)McN5652 for PET appear to meet the criteria of a useful radioligand. There is still a need for the development of new radioligands for SERT imaging. Advances in tracer synthetic methodologies may bring further progress in this field.

14.
Nucl Med Biol ; 25(7): 599-603, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9804040

ABSTRACT

The in vivo brain regional distribution of 2-[18F]fluoro-A-85380, a novel tracer for positron emission tomographic (PET) studies, followed the regional densities of brain nAChRs reported in the literature. Evidence of binding to nAChRs and high specificity of the binding in vivo was demonstrated by inhibition with nAChR selective ligands as well as with unlabeled 2-fluoro-A-85380. A preliminary toxicology study of the 2-fluoro-A-85380 showed a relatively low biological effect. 2-[18F]Fluoro-A-85380 holds promise as a useful radiotracer for imaging of nAChRs with PET.


Subject(s)
Azetidines/pharmacokinetics , Receptors, Nicotinic/metabolism , Animals , Azetidines/metabolism , Azetidines/toxicity , Binding, Competitive/drug effects , Fluorine Radioisotopes , Injections, Intravenous , Male , Mice , Receptors, Nicotinic/analysis , Tissue Distribution
15.
Lancet ; 352(9138): 1433-7, 1998 Oct 31.
Article in English | MEDLINE | ID: mdl-9807990

ABSTRACT

BACKGROUND: (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") is a popular recreational drug that selectively damages brain serotonin (5-HT) neurons in animals at doses that closely approach those used by humans. We investigated the status of brain 5-HT neurons in MDMA users. METHODS: We enrolled 14 previous users of MDMA who were currently abstaining from use and 15 controls who had never used MDMA. We used positron emission tomography (PET) with the radioligand carbon-11-labelled McN-5652, which selectively labels the 5-HT transporter. We analysed whether there were differences in 5-HT transporter binding between abstinent MDMA users and participants in the control group. Blood and urine samples were taken and tested to check for abstinence. FINDINGS: MDMA users showed decreased global and regional brain 5-HT transporter binding compared with controls. Decreases in 5-HT transporter binding positively correlated with the extent of previous MDMA use. INTERPRETATION: Quantitative PET studies with a ligand selective for 5-HT transporters can be used to assess the status of 5-HT neurons in the living human brain. We show direct evidence of a decrease in a structural component of brain 5-HT neurons in human MDMA users.


Subject(s)
Brain/drug effects , N-Methyl-3,4-methylenedioxyamphetamine/adverse effects , Neurons/drug effects , Serotonin Agents/adverse effects , Serotonin/metabolism , Adult , Female , Humans , Male , Neurons/metabolism , Tomography, Emission-Computed
16.
J Med Chem ; 41(22): 4199-206, 1998 Oct 22.
Article in English | MEDLINE | ID: mdl-9784094

ABSTRACT

Four halogen-substituted analogues of N-methylepibatidine, a nicotinic acetylcholine receptor (nAChR) ligand, were synthesized. They were (+/-)-exo-N-methyl-2-(2-halogeno-5-pyridyl)-7-azabicyclo[2. 2.1]heptanes, where halogeno = F (1a), Cl (2a), Br (3a), I (4a). (+/-)-N-Ethylepibatidine (2b) also was synthesized. The compounds 1a, 2a, 3a, and 4a and their corresponding normethyl analogues 1, 2, 3, and 4 inhibited the in vitro binding of [3H]epibatidine to nAChRs to a similar degree, with affinities in the 27-50 pM range. The binding affinity of N-ethylepibatidine (2b), however, was substantially lower. The N-[11C]methyl derivatives of 1, 2, and 3 were synthesized from high-specific radioactivity [11C]methyl iodide using a high-temperature/high-pressure technique. The corresponding radiolabeled compounds [11C]1a, [11C]2a, and [11C]3a were administrated to mice intravenously. The pattern of regional distribution of the three tracers in the mouse brain following intravenous administration matched those of [3H]epibatidine, [3H]norchloroepibatidine, and (+/-)-exo-2-(2-[18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane ([18F]FPH), which are highly specific nAChR probes. The initial brain uptake of the 11C analogues and the acute toxicity of the corresponding authentic nonlabeled compounds appeared to be related to their lipophilicity.


Subject(s)
Bridged Bicyclo Compounds, Heterocyclic/chemical synthesis , Pyridines/chemical synthesis , Radiopharmaceuticals/chemical synthesis , Receptors, Nicotinic/metabolism , Animals , Brain/diagnostic imaging , Brain/metabolism , Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics , Bridged Bicyclo Compounds, Heterocyclic/toxicity , Carbon Radioisotopes , Injections, Intravenous , Lethal Dose 50 , Male , Mice , Pyridines/pharmacokinetics , Pyridines/toxicity , Radiopharmaceuticals/pharmacokinetics , Radiopharmaceuticals/toxicity , Tissue Distribution , Tomography, Emission-Computed
17.
Synapse ; 30(1): 116-8, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9704889

ABSTRACT

Up-regulation of brain nicotinic receptors (nAChRs) by chronic nicotine treatment has chiefly been demonstrated by in vitro binding assays. Here, we report that up-regulation of nAChRs in CD-1 mice can be detected using a specific in vivo radioligand for nAChRs, [125I]IPH. After 10 days of (-)-nicotine administration, male and female mice demonstrated a significant elevation of [125I]IPH binding in all brain regions studied. [125I]IPH uptake also displayed significant gender differences with male animals showing a more pronounced increase in [125I]IPH accumulation.


Subject(s)
Brain/metabolism , Nicotine/pharmacology , Receptors, Nicotinic/biosynthesis , Up-Regulation/drug effects , Animals , Brain/drug effects , Bridged Bicyclo Compounds, Heterocyclic/pharmacokinetics , Female , Iodine Radioisotopes , Male , Mice , Nicotinic Agonists/pharmacokinetics , Pyridines/pharmacokinetics , Radioligand Assay , Sex Characteristics
18.
Eur J Pharmacol ; 350(2-3): 335-44, 1998 Jun 05.
Article in English | MEDLINE | ID: mdl-9696425

ABSTRACT

Naltriben (NTB) is a selective antagonist for the putative delta2-opioid receptor. We have determined the regional kinetics and pharmacological profile of [3H]naltriben in vivo in mouse brain. After i.v. administration to CD1 mice, [3H]naltriben uptake and retention were high in striatum, cortical regions and olfactory tubercles, and low in superior colliculi and cerebellum. Robust rank order correlation was found between [3H]naltriben uptake in discrete brain regions and prior delta-opioid receptor binding determinations in vitro and in vivo. [3H]Naltriben binding in vivo was saturable, and was blocked by the delta-opioid receptor antagonist naltrindole, but not by the mu-opioid receptor antagonist cyprodime or the K-opioid receptor agonist (trans)-(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]ben zeneacetamide mesylate (U50,488H). (E)-7-Benzylidenenaltrexone (BNTX), a selective antagonist for the putative delta1-opioid receptor, was 9.6- to 12.9-fold less potent than naltriben as an inhibitor of [3H]naltriben binding. Thus, the sites labeled by [3H]naltriben in vivo may correspond to the delta2-opioid receptor subtype. Such assignment is not definitive, particularly considering the 4-fold higher brain uptake of naltriben as compared to (E)-7-benzylidenenaltrexone. Moreover, the regional distribution of [3H]naltriben in brains from CXB-7/BY (CXBK) mice, a strain that shows supraspinal delta1- but not delta2-opioid receptor agonist effects, was quite similar to that found for CD1 mice.


Subject(s)
Brain/metabolism , Naltrexone/analogs & derivatives , Narcotic Antagonists/pharmacokinetics , Receptors, Opioid, delta/metabolism , Animals , Binding, Competitive/drug effects , Injections, Intravenous , Male , Mice , Mice, Inbred Strains , Naltrexone/pharmacokinetics , Naltrexone/pharmacology , Narcotic Antagonists/pharmacology , Receptors, Opioid, delta/antagonists & inhibitors
19.
J Nucl Med ; 39(7): 1209-13, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9669396

ABSTRACT

UNLABELLED: Antagonists of the angiotensin II AT1 receptor subtype have been recently introduced for treatment of arterial hypertension and for pharmacological studies of these receptors. The purpose of this work was to label such an antagonist with 11C and test the applicability of the radioligand for PET studies. METHODS: The potent and selective nonpeptide AT1 antagonist L-159,884 was labeled with 11C and injected intravenously into six dogs. Renal accumulation and kinetics of the radioligand were imaged with PET at baseline and after receptor blockade with 1 mg/kg MK-996. Time-activity curves were derived from the renal cortex and were analyzed by the Gjedde-Patlak plot to obtain the influx rate constant of the radioligand. RESULTS: There was selective radioligand binding in the kidneys, mainly located in the cortex. Within the time interval between 95 and 115 min postinjection, the radioactivity retained in the kidneys was 109 +/- 27 and 42 +/- 4 nCi/ml/mCi of the injected dose for the control and inhibition studies, respectively. The influx rate constant of the radioligand decreased from a baseline of 0.0298 +/- 0.0156 to a post-MK-996 value of 0.0098 +/- 0.0052. CONCLUSION: These results demonstrate distinct binding of 11C-L-159,884 in the renal cortex with a specific binding component suitable for quantitative PET imaging of angiotensin II/AT1 receptors.


Subject(s)
Angiotensin II/antagonists & inhibitors , Carbon Radioisotopes , Imidazoles , Kidney Cortex/diagnostic imaging , Pyridines , Receptors, Angiotensin/metabolism , Tomography, Emission-Computed , Angiotensin Receptor Antagonists , Animals , Dogs , Feasibility Studies , Kidney Cortex/metabolism , Radioligand Assay , Time Factors
20.
Life Sci ; 63(1): PL13-8, 1998.
Article in English | MEDLINE | ID: mdl-9667769

ABSTRACT

[11C]A-84543, 3-[(1-[11C]methyl-2(S)-pyrrolidinyl)methoxy]pyridine, is a specific and enantioselective neuronal nicotinic acetylcholine receptor (nAChR) radiotracer. The in vivo biodistribution of this radiotracer in mice showed high brain uptake and a distribution consistent with the density of nAChRs. Highest uptake was observed in the thalamus (9.6 %ID/g), cortex (9.9 %ID/g), superior colliculus (7.6 %ID/g) and hippocampus (7.6 %ID/g) at 5 min followed by clearance. As a measure of specificity, the thalamus/cerebellar ratio reached a maximum of 2.3 at 30 min post-injection. Radioactivity in the thalamus and superior colliculus was reduced by 33% by pre-administration of unlabeled A-84543. The nAChR agonists (-)nicotine, cytisine, and (+) epibatidine reduced the radioactivity due to [11C]A-84543 in the superior colliculus by 41%, 38%, and 27%, respectively, while lobeline, which also interacts with central nAChRs, produced a 24% inhibition. The noncompetitive nAChR ligand, mecamylamine displayed no inhibitory effect on [11C]A-84543 accumulation in any brain region. Ketanserin (5-HT2/5-HT2C), scopolamine (mAChR antagonist), (+)butaclamol (DA receptor antagonist), and haloperidol (D2/sigma) also displayed no inhibitory effect in any brain region studied. With the pharmacologically less active enantiomer, 3-[(1-[11C]methyl-2(R)-pyrrolidinyl)methoxy] pyridine, high brain uptake was also observed, but with a low thalamus/cerebellar ratio of 1.4 at 30 min post-injection. [11C]A-84543 displays enantioselectivity for nAChRs and may deserve further investigation as a possible PET radiotracer.


Subject(s)
Brain/metabolism , Neurons/metabolism , Pyrrolidines/pharmacokinetics , Receptors, Nicotinic/metabolism , Animals , Carbon Radioisotopes/pharmacokinetics , Ligands , Male , Mice , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...